Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Price Performance

CTNM stock opened at $9.37 on Tuesday. The business’s 50-day simple moving average is $13.44 and its 200 day simple moving average is $16.36. Contineum Therapeutics has a twelve month low of $9.19 and a twelve month high of $22.00.

Analyst Ratings Changes

CTNM has been the subject of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Baird R W raised shares of Contineum Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Robert W. Baird began coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).